Propanc Biopharma, Inc. (OTCMKTS:PPCB – Get Free Report)’s stock price rose 108.3% during mid-day trading on Thursday . The company traded as high as $145.46 and last traded at $25.00. Approximately 753 shares traded hands during mid-day trading, a decline of 100% from the average daily volume of 11,821,764 shares. The stock had previously closed at $12.00.
Propanc Biopharma Price Performance
The business has a 50 day simple moving average of $0.50 and a 200-day simple moving average of $0.17.
Propanc Biopharma Company Profile
Propanc Biopharma, Inc, a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes.
Read More
- Five stocks we like better than Propanc Biopharma
- 3 Warren Buffett Stocks to Buy Now
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- Buy P&G Now, Before It Sets A New All-Time High
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- The Significance of Brokerage Rankings in Stock Selection
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Propanc Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Propanc Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
